ME Live signals | Maximize Profits with Getagraph.com

BUY 92845 min ago

@ $0.773

Issued: 14 Feb 2024 @ 15:29

Return: -34.59%

Previous signal: Feb 14 - 10:21

Previous signal: Sell

Return: 3.62 %

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics...

Stats
Today's Volume	59.00M
Average Volume	6.61M
Market Cap	244.11M
EPS	$0 ( 2024-02-07 )
Next earnings date	( $-0.150 ) 2024-05-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.460
ATR14	$0.00300 (0.61%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-04	Hibbs Kathy L	Buy	38 548	Class A Common Stock
2024-04-04	Hibbs Kathy L	Sell	38 548	Class A Common Stock
2024-04-04	Hibbs Kathy L	Sell	38 548	Stock Option (Right to Buy)
2024-03-21	Hibbs Kathy L	Buy	38 548	Class A Common Stock
2024-03-21	Hibbs Kathy L	Sell	38 548	Class A Common Stock

INSIDER POWER
74.39
Last 100 transactions
Buy: 15 289 110 \| Sell: 2 056 788

Volume Correlation

Long: 0.39 (neutral)

Short: 0.44 (neutral)

Signal:(40.419) Neutral

23andMe Holding Co. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

23andMe Holding Co. Correlation - Currency/Commodity

0.00
( neutral )

-0.01
( neutral )

0.00
( neutral )

0.05
( neutral )

23andMe Holding Co. Financials

Annual	2022
Revenue:	$299.49M
Gross Profit:	$134.50M (44.91 %)
EPS:	$-0.690

Q3	2023
Revenue:	$44.75M
Gross Profit:	$19.94M (44.55 %)
EPS:	$-0.580

Q2	2023
Revenue:	$50.00M
Gross Profit:	$21.73M (43.46 %)
EPS:	$-0.160

Q1	2023
Revenue:	$60.86M
Gross Profit:	$30.68M (50.41 %)
EPS:	$-0.230

Financial Reports:

No articles found.

23andMe Holding Co.

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.